KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Non-Current Liabilities (2016 - 2025)

Rigel Pharmaceuticals has reported Total Non-Current Liabilities over the past 16 years, most recently at $122.1 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 21.56% year-over-year to $122.1 million; the TTM value through Dec 2025 reached $122.1 million, down 21.56%, while the annual FY2025 figure was $122.1 million, 21.56% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $122.1 million at Rigel Pharmaceuticals, down from $152.4 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $155.7 million in Q4 2024 and troughed at $80.2 million in Q1 2021.
  • A 5-year average of $105.8 million and a median of $105.7 million in 2022 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 46.98% in 2024 and later decreased 21.56% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $84.2 million in 2021, then increased by 25.41% to $105.6 million in 2022, then increased by 0.28% to $105.9 million in 2023, then skyrocketed by 46.98% to $155.7 million in 2024, then dropped by 21.56% to $122.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for RIGL at $122.1 million in Q4 2025, $152.4 million in Q1 2025, and $155.7 million in Q4 2024.